Crescent Biopharma Inc 宣布,将在即将到来的2026年美国临床肿瘤学会(ASCO)年会上,就其PD-1 x VEGF双特异性抗体CR-001的Ascend研究,进行“试验进展”报告。
Crescent Biopharma Inc 宣布,将在即将到来的2026年美国临床肿瘤学会(ASCO)年会上,就其PD-1 x VEGF双特异性抗体CR-001的Ascend研究,进行“试验进展”报告。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.